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ABSTRACT
Objectives To determine whether baseline 
demographic, clinical, articular and laboratory 
variables predict methotrexate (MTX) poor response in 
polyarticular-course juvenile idiopathic arthritis.
Methods Patients newly treated for 6 months with MTX 
enrolled in the Paediatric Rheumatology International 
Trials Organization (PRINTO) MTX trial. Bivariate and 
logistic regression analyses were used to identify baseline 
predictors of poor response according to the American 
College of Rheumatology pediatric (ACR-ped) 30 and 70 
criteria.
Results In all, 405/563 (71.9%) of patients were 
women; median age at onset and disease duration 
were 4.3 and 1.4 years, respectively, with anti-nuclear 
antibody (ANA) detected in 259/537 (48.2%) patients. 
With multivariate logistic regression analysis, the most 
important determinants of ACR-ped 70 non-responders 
were: disease duration >1.3 years (OR 1.93), ANA 
negativity (OR 1.77), Childhood Health Assessment 
Questionnaire (CHAQ) disability index>1.125 (OR 1.65) 
and the presence of right and left wrist activity (OR 1.55). 
Predictors of ACR-ped 30 non-responders were: ANA 
negativity (OR 1.92), CHAQ disability index>1.14 (OR 
2.18) and a parent’s evaluation of child’s overall well-
being ≤4.69 (OR 2.2).
Conclusion The subgroup of patients with longer 
disease duration, ANA negativity, higher disability and 
presence of wrist activity were signifi cantly associated 
with a poorer response to a 6-month MTX course.
INTRODUCTION
Methotrexate (MTX) up to 15 mg/m2/week for 
9–12 months is the second line agent of fi rst choice 
for the treatment of children with polyarticular-
course juvenile idiopathic arthritis (JIA) who do 
not respond to non-steroidal anti-infl ammatory 
drugs.1–3 About one-third of these patients do not 
respond or are intolerant to MTX and are, therefore, 
candidates for treatment with biological agents.4–7
Knowledge of predictive factors of poor drug 
response is of great value in clinical practice8–10 to 
identify patients who are likely to have progressive 
disease and may need aggressive treatment earlier.
The purpose of the present study, conducted by 
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Organization (PRINTO)11 was to determine, in a post 
hoc trial analysis, whether baseline demographic, 
clinical, articular and laboratory variables can be used 
to predict poor response to treatment with MTX.
METHODS
Patient selection
Patients were extracted from the PRINTO database 
containing the results of a randomised trial aimed 
to evaluate the effi cacy and safety profi le of MTX 
in polyarticular-course patients with JIA12 13 (rheu-
matoid factor (RF) negative, psoriatic arthritis and 
enthesitis-related arthritis excluded) as previously 
described.2 A total of 563/595 (94.6%) patients with 
baseline and 6 months follow-up were included.
Evaluation of response to treatment
After 6 months of MTX treatment, patients were 
divided into responders and non-responders, accord-
ing to the American College of Rheumatology pedi-
atric (ACR-ped) 30 or 70 improvement criteria14: 
at least 30 or 70% (ACR-ped 30 or 70) improve-
ment from baseline in at least three of any six JIA 
core set variables (doctor’s and parent’s evalua-
tion, number of active joints and joint with limited 
range of motion, Childhood Health Assessment 
Questionnaire (CHAQ), erythrocyte sedimentation 
rate (ESR)) with no more than one of the remaining 
variables worsened by more than 30%.
Potential baseline predictors of response included 
demographic (gender, age at onset, at visit and dis-
ease duration), clinical (JIA subtype, uveitis, core set 
parameters), articular (76 individual or combined 
group of joints) and laboratory variables (anti-nuclear 
antibody (ANA) positivity according to International 
League of Associations for Rheumatology (ILAR) cri-
teria, and ESR), as derived from the literature,1 3 9 15–30 
and as detailed in tables 1 and 2.
Statistics
Descriptive statistics were reported in terms of 
medians with fi rst and third quartiles for quantita-
tive variables and in terms of absolute frequencies 
and percentages for qualitative variables.
In the bivariate analysis the comparison of quan-
titative variables between two groups of patients 
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Table 1 Demographic and clinical characteristics of the study patients at baseline; patients are divided into responders and non-responders based 
on the American College of Rheumatology pediatric (ACR-ped) 30 and 70 dichotomous level of response
Characteristics
ACR-ped 30 responders 
(430 (76.4%))
ACR-ped 30 non-responders 
(133 (23.6%))
ACR-ped 70 responders 
(225 (40%))
ACR-ped 70 non-responders 
(338 (60%))
Demographics, N (%)
Female 309 (71.9%) 96 (72.2%) 162 (72.0%) 243 (71.9%)
Age group
≤ 4 years 104 (24.2%) 25 (18.8%) 58 (25.8%) 71 (21.0%)
>4 and ≤ 8 years 116 (27.0%) 44 (33.0%) 66 (29.3%) 94 (27.8%)
>8 and ≤ 12 years 129 (30.0%) 32 (24.1%) 58 (25.8%) 103 (30.5%)
>12 years 81 (18.8%) 32 (24.1%) 43 (19.1%) 70 (20.7%)
JIA subtypes
Polyarthritis RF negative 243 (56.5%) 63 (47.4%) 123 (54.7%) 183 (54.1%)
Extended oligoarthritis 132 (30.7%) 44 (33.1%) 71 (31.5%) 105 (31.1%)
Systemic onset arthritis with 
polyarticular course
55 (12.8%) 26 (19.5%) 31 (13.8%) 50 (14.8%)
ANA
 Positive 214/409 (52.3%)*** 45/128 (35.2%) 122/209 (58.4%)*** 137/328 (41.8%)
 Negative 195/409 (47.7%) 83/128 (64.8%) 87/209 (41.6%) 191/328 (58.2%)
NSAIDs 350 (81.4%) 108 (81.2%) 177 (78.7%) 281 (83.1%)
Steroids 108 (25.1%) 44 (33.1%) 61 (27.1%) 91 (26.9%)
MTX oral 330/428 (77.1%) 107 (80.5%) 168/224 (75%) 269/337 (79.8%)
MTX dose, mg/m2/week (N=557) 10 (9.1–11.1) 10 (8.9–11.4) 10 (9.1–11.1) 10 (9–11.4)
Age at onset, years 4.4 (1.9–8.4) 4.2 (2.2–8.4) 4.4 (1.9–8.5) 4.3 (2.1–8.3)
Age at visit, years 7.8 (4.3–11.2) 7.5 (4.7–11.8) 7.3 (3.7–11.3) 8.1 (4.6–11.5)
Disease duration, years 1.3 (0.6–3.5) 1.7 (0.8–3.7) 1 (0.6–2.4)*** 1.7 (0.8–3.7)
ESR (N=556) 40 (22–63) 37.5 (20–57.5) 44 (26–65)** 36 (20–59)
Doctor evaluation of physical 
well-being (N=559)
5.2 (3.7–6.6) 4.9 (3.7–7.0) 5.2 (3.8–6.6) 5.0 (3.6–6.6)
Parent’s evaluation of child’s overall well-being 4.6 (2.3–6.4)* 3.7 (2.0–6.1) 4.6 (2.2–6.2) 4.2 (2.2–6.3)
Parent’s evaluation of child’s pain (N=560) 4.7 (2.5–7.0) 4.4 (2.4–6.3) 4.5 (2.4–7.1) 4.5 (2.4–6.8)
CHAQ disability index 1.12 (0.62–1.75) 1.37 (0.62–1.87) 1 (0.62–1.62)* 1.37 (0.62–1.87)
CHQ PhS (N=438) 40.4 (29.6–46.9) 40.9 (32.4–46.5) 40.4 (29.7–47.9) 40.5 (30.8–46.4)
CHQ PsS (N=438) 46.1 (37.9–51.1) 46.8 (39.7–52.6) 46.1 (37.7–51.3) 46.4 (38.3–51.5)
Data are N (%) or median (fi rst to third quartile). The denominator is indicated in the table header unless otherwise stated (eg, ANA or CHQ). Comparisons of frequencies was by χ2 
test, comparison of quantitative variables was by Mann–Whitney U test.
*p<0.05; **p<0.01; ***p<0.001.
ANA, anti-nuclear antibody; CHAQ, Childhood Health Assessment Questionnaire; CHQ, Child Health Questionnaire; ESR, erythrocyte sedimentation rate; JIA, juvenile idiopathic arthritis; 
MTX, methotrexate; NSAID, non-steroidal anti-infl ammatory drug; PhS, physical summary; PsS, psychosocial summary; RF, rheumatoid factor.
Table 2 Articular parameters of the study patients at baseline; patients are divided into responders and nor responders based on the American 
College of Rheumatology pediatric (ACR-ped) 30 and 70 criteria
Characteristics
ACR-ped 30 responders 
(430 (76.4%))
ACR-ped 30 non-responders 
(133 (23.6%))
ACR-ped 70 responders 
(225 (40%))
ACR-ped 70 non-responders 
(338 (60%))
Articular parameters
No. of active joints 9 (6–15) 10 (6–19) 8 (6–13)* 10 (6–18)
No. of joints with pain 7 (4–13) 8 (4–15) 7 (4–12) 8 (4–15)
No. of swollen joints 7 (4–13) 7 (4–14) 6 (4–11)* 7 (4–14)
No. of joints with limited range of motion 8 (5–13) 7 (4–14) 7 (5–11) 8 (4–15)
Specifi c joints involvement†
Wrist: right and left activity 211 (49.1%) 77 (57.9%) 95 (42.2%)** 193 (57.1%)
Wrist: ≥1 active 283 (65.8%) 95 (71.4%) 138 (61.3%)* 240 (71%)
MCP 1: right and left activity 52 (12.1%)* 27 (20.3%) 19 (8.4%)** 60 (17.8%)
MCP 1: ≥1 active 98 (22.8%) 35 (26.3%) 41 (18.2%)* 92 (27.2%)
MCP 2: ≥1 active 156 (36.3%) 57 (42.9%) 69 (30.7%)* 144 (42.6%)
MCP 3: ≥1 active 141 (32.8%) 46 (34.6%) 60 (26.7%)* 127 (37.6%)
PIP 1: right and left activity 59 (13.7%)** 32 (24.1%) 30 (13.3%) 61 (18%)
PIP 2: right and left activity 111 (25.8%)* 48 (36.1%) 52 (23.1%)* 107 (31.7%)
Knee: ≥1 active 351 (81.6%)* 98 (73.7%) 189 (84%)* 260 (76.9%)
Data are N (%) or median (fi rst to third quartile). The denominator is indicated in the table header. Comparisons of frequencies was by χ2 test, comparison of quantitative variables was 
by Mann–Whitney U test.
*p<0.05; **p<0.01; ***p<0.001.
†For joint involvement only statistically signifi cant associations are reported.
MCP, metacarpophalangeal; PIP, proximal interphalangeal.
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(ACR-ped 30 or 70 responders versus non-responders) was 
made by the Student’s t test or by the Mann–Whitney U test as 
appropriate, and the comparison of frequencies by the χ2 test.
A logistic regression analysis was then performed to evaluate 
the role of baseline variables with ACR-ped 30 or 70 non-re-
sponders to MTX. Statistically signifi cant variable (p value<0.05), 
in the bivariate analysis, were entered into the model. ORs, 95% 
CIs and the likelihood ratio test were reported.
The programs Statistica 6 (StatSoft, Tulsa, Oklahoma, USA) 
and Stata 7 (Stata, College Station, Texas, USA) were used.
RESULTS
Of the 563/595 patients (94.6%) available for this analysis, 405 
(71.9%) were women. Their median age (fi rst to third quartiles) 
at onset was 4.3 (1.9–8.4) years, age at study entry 7.7 (4.3–11.4) 
and disease duration 1.4 (0.7–3.6). The JIA category was polyar-
ticular RF negative in 306 (54.3%), extended oligoarticular in 176 
(31.3%) and systemic with polyarticular course in 81 (14.4%) 
patients. ANA were detected in 259/537 (48.2%) patients, and 
a history of chronic uveitis was present in 74/546 (13.6%) of 
patients. At baseline, patients had a median of 9 active joints 
(6–16), a doctor evaluation of disease activity of 5.1 (3.7–6.6), 
ESR of 40 mm/I h (21–62), a parent evaluation of child’s over-
all well-being of 4.4 (2.2–6.3), a CHAQ disability index of 1.25 
(0.63–1.75) and a Child Health Questionnaire (CHQ) physical 
well-being of 40.4 (30.5–46.9).
Bivariate analysis
Tables 1 and 2 show the demographic, laboratory, clinical and 
articular parameters of the patients at study entry divided into 
ACR-ped 30 and 70 responders and non-responders.
Among the disease characteristics reported in table 1, poor 
response to MTX according to ACR-ped 30 or 70 criteria was 
associated with ANA negativity (p<0.001). In addition, poor 
response according to ACR-ped 70 criteria was associated with 
longer median disease duration, lower values of ESR and a 
higher CHAQ level of disability, while a lower parent’s evalu-
ation of child’s well-being was associated with poor response 
only according to ACR-ped 30 criteria.
As shown in table 2, when we considered specifi c patterns of 
joint involvement, poor response to MTX according to the ACR-
ped 70 criteria was associated with the presence of right and left 
wrist metacarpophalangeal (MCP) 1 activity (p<0.01), ≥1 wrist, 
MCP 1-2-3, right and left proximal interphalangeal (PIP)s 2, ≥1 
knee (all p<0.05). Similar results were obtained for ACR-ped 30 
response.
Multivariate analysis
All variables that were signifi cantly associated with ACR-ped 
30 or 70 poor response were entered into the multivariate logis-
tic regression analysis (table 3). The baseline determinants for 
poor MTX response according to the ACR-ped 70 criteria were 
longer disease duration (>1.3 years; OR=1.93), negative ANA 
(OR=1.77), CHAQ disability index >1.125 (OR=1.65) and the 
presence of right and left wrist activity (OR=0.65) (eg, patients 
with both active wrists responded to a lower extent to MTX). 
Predictors for poor response according to the ACR-ped 30 cri-
teria were similarly ANA negativity, CHAQ disability and, in 
addition, the parent’s evaluation of overall child well-being.
DISCUSSION
In the present study, we have sought for predictors of poor 
response to a 6-month MTX course in the context of the 
PRINTO trial.2 It has been argued that only an improvement 
in disease activity measures above an ACR-ped 70 threshold 
refl ects a major clinical response to treatment29 and predicts a 
more favourable long-term disease outcome in patients with 
polyarticular-course JIA.15
Although it is commonly believed that drug treatments may 
be more effective if administered early in the course of rheu-
matoid arthritis28 or JIA,16 little evidence-based data exist to 
support this view. In our study a longer disease duration (>1.3 
years) at baseline was the strongest predictor of poorer thera-
peutic response, suggesting that precocious introduction of sec-
ond-line medications, in patients who deserve such treatment, 
increases the likelihood of response.
Previous reports of factors associated with MTX effi cacy have 
provided confl icting results. Halle and Prieur17 observed that 
patients who were ANA positive or with polyarticular onset 
and course were more sensitive to MTX than those with the 
systemic subtype. Woo et al3 found that MTX was an effec-
tive treatment for extended oligoarticular and systemic JIA in 
a crossover trial. However, Giannini et al1 30 reported an equal 
response rate among JIA onset subtypes. We previously found 
that the extended oligoarticular subtype was the best predictor 
for short-term clinical response to MTX.9 In the present study 
the frequency of ILAR categories of JIA was comparable between 
responders and non-responders. However, ANA negativity was 
found to be strongly associated with a poorer response to MTX 
in multivariate analysis, in keeping with previous observation 
that ANA-positive patients with JIA represent a homogeneous 
subtype18 associated with lower disability in children with ≥5 
years of disease duration.19 20
The fi nding that a higher level of disability (CHAQ>1.125) 
at baseline was associated with a greater likelihood of poorer 
response to MTX is in line with the common view that patients 
with greater functional impairment/damage are less likely to 
respond to drug treatments. Patients with JIA with marked 
functional impairment have been found to have a greater risk 
of developing long-term physical disability21 and poorer Health-
Related Quality of Life (HRQOL).22 These fi ndings suggest that 
early development of functional impairment represents an indi-
cation to the start of a more aggressive treatment with biological 
agents.
Arthritis in both wrists was the best predictor of MTX poor 
response, with patients who lacked such involvement being more 
likely to benefi t from MTX treatment. It has been suggested that 
Table 3 Logistic regression models obtained from the evaluations 
of the determinants of the non-response to MTX, according to the 
American College of Rheumatology pediatric (ACR-ped) 30 and 70 
defi nition of improvement
Determinants of non-response OR (95% CI) p Value*
ACR-ped 30 non-responders (N=128/537 (23.8%)):
ANA negative 1.92 (1.26 to 2.92) 0.002
CHAQ-DI >1.14 2.18 (1.40 to 3.84) 0.0004
Parent’s evaluation of overall well-being ≤4.69 2.20 (1.41 to 3.42) 0.0004
Area under ROC curve of the model 0.65
ACR-ped 70 non-responders (N=328/537 (61.1%)):
Disease duration >1.339 years 1.93 (1.34 to 2.77) 0.0003
ANA negative 1.77 (1.23 to 2.55) 0.002
CHAQ-DI >1.125 1.65 (1.15 to 2.38) 0.006
Wrist: right and left activity 1.55 (1.07 to 2.23) 0.019
Area under ROC curve of the model 0.66
* Likelihood ratio test.
ANA, anti-nuclear antibody; CHAQ-DI, Childhood Health Assessment Questionnaire 
Disability Index; MTX, methotrexate; ROC, receiver operating characteristic.
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patients with JIA with polyarthritis and wrist disease are at high 
risk of experiencing radiographic progression,23 24 a more severe 
course of arthritis,9 25 a poorer functional outcome26 or a lesser 
likelihood of short-term therapeutic response.18 Altogether, 
these observations emphasise the importance of considering the 
presence of wrist disease as a marker of poor prognosis in chil-
dren with JIA.
Limitations of the current work include that the pattern of 
joint involvement and the observed response rate in JIA can-
not be directly compared to adult rheumatoid arthritis due to 
known heterogeneity of JIA in <5% of the children with RF pos-
itivity.27 Additionally, baseline predictors for a 6-month course 
of MTX may be different than predictors for a 12-month course 
of MTX.
In conclusion, we have found that longer disease duration, 
ANA negativity, a higher level of disability and presence of wrist 
activity at baseline were signifi cantly associated with a greater 
likelihood of ACR-ped 70 non-response to a 6-month course of 
MTX, suggesting that MTX may be distinctly less effective in 
this subgroup of patients. The presence of these baseline deter-
minants may help doctors to identify patients who might ben-
efi t from an earlier treatment with biological drugs.
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